Traduction de «medicines can be used » (Néerlandais → Français) :

1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines
1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines

Advisory commission which is consulted e.g. in cases of non-availability of medicines Commission for the approval of institutions assigning preliminary approvals for scientific events Commission for the establishment of retail pharmacies and chambers of appeal (Frenchspeaking chamber and Dutch-speaking chamber) Commission for the recognition of pharmacists-clinical biologists Commission for the supervision of advertising for medicines for human use Evaluation commission for active implantable medical devices Evaluation commission for homeopathic medicines Evaluation commission for medical devices Evaluation commission for medicines for human use Evaluation commission for medicines for veterinary use Evaluation commission for traditional herbal medicines Pharmacopoeia commission
Advisory commission which is consulted e.g. in cases of non-availability of medicines Commission for the approval of institutions assigning preliminary approvals for scientific events Commission for the establishment of retail pharmacies and chambers of appeal (Frenchspeaking chamber and Dutch-speaking chamber) Commission for the recognition of pharmacists-clinical biologists Commission for the supervision of advertising for medicines for human use Evaluation commission for active implantable medical devices Evaluation commission for homeopathic medicines Evaluation commission for medical devices Evaluation commission for medicines for human use Evaluation commission for medicines for veterinary use Evaluation commission for traditional herbal medicines Pharmacopoeia commission

Evaluation commission for active implantable medical devices Evaluation commission for homeopathic medicines Evaluation commission for medical devices Evaluation commission for medicines for human use Evaluation commission for medicines for veterinary use Evaluation commission for traditional herbal medicines
Evaluation commission for active implantable medical devices Evaluation commission for homeopathic medicines Evaluation commission for medical devices Evaluation commission for medicines for human use Evaluation commission for medicines for veterinary use Evaluation commission for traditional herbal medicines

Evaluation commission for active implantable medical devices Evaluation commission for homeopathic medicines Evaluation commission for medical devices Evaluation commission for medicines for human use Evaluation commission for medicines for veterinary use Evaluation commission for traditional herbal medicines Pharmacopoeia commission
Evaluation commission for active implantable medical devices Evaluation commission for homeopathic medicines Evaluation commission for medical devices Evaluation commission for medicines for human use Evaluation commission for medicines for veterinary use Evaluation commission for traditional herbal medicines Pharmacopoeia commission

Herbal medicinal products In line with the provisions of the royal decree of 14 December 2006, three procedures are used for the issue of the MA or registration for herbal medicinal products: the full procedure, the “Well Established Use” procedure and a third specific procedure for traditional herbal medicines as stipulated in article 43 of the royal decree.
Herbal medicinal products In line with the provisions of the royal decree of 14 December 2006, three procedures are used for the issue of the MA or registration for herbal medicinal products: the full procedure, the “Well Established Use” procedure and a third specific procedure for traditional herbal medicines as stipulated in article 43 of the royal decree.

The FAMHP and the BUM department in particular ensures that all parties have access to such information, so that medicines can be used rationally and safely.
The FAMHP and the BUM department in particular ensures that all parties have access to such information, so that medicines can be used rationally and safely.

The database can be used to look up extensive information about authorised medicines without having to contact those responsible for providing information, as is currently the case ●● Healthcare professionals and veterinarians
The database can be used to look up extensive information about authorised medicines without having to contact those responsible for providing information, as is currently the case ●● Healthcare professionals and veterinarians

De gegevens over de veiligheid van aliskiren werden recent herbekeken door het Committee for Medicinal Products for Human Use (CHMP) van het European Medicines Agency (EMA) [ www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2012/02/WC500122916.pdf ].
Les données concernant le profil d’innocuité de l’aliskirène ont été récemment revues par le Committee for Medicinal Products for Human Use (CHMP) de l’Agence européenne des médicaments (EMA) [ www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2012/02/ WC500122916.pdf ].

Deze terugkerende trend, meer cardiovasculaire problemen met COX 2-selectieve middelen, is voor vele onderzoekers en commentatoren een reden van bezorgdheid [ Can Med Assoc J 167 : 1131-1137(2002); Worst Pills Best Pills 10 : 65-68(2004); Lancet 364 : 639-640(2004) ; Brit Med J 329 : 867-868(2004) ; de hierboven vermelde recente artikels in Lancet en New England Journal of Medicine].
Pour beaucoup d’investigateurs et de commentateurs, cette tendance récurrente à plus de problèmes cardio-vasculaires avec les AINS COX-2 sélectifs suscite des inquiétudes [ Can Med Assoc J 167 : 1131-1137(2002); Worst Pills Best Pills 10 : 65-68(2004); Lancet 364 : 639-640(2004) ; Brit Med J 329 : 867-868(2004) ; les articles récents du Lancet et du New England Journal of Medicine mentionnés plus haut].

De " hulpstoffen met erkende werking" (met de toedieningsweg en de drempelwaarde vanaf dewelke effecten mogelijk zijn, en met uitleg over de risicogroepen) zijn gedefinieerd in het richtsnoer van de Europese Commissie " Excipients in the label and package leaflet of medicinal product for human use" (juli 2003, te raadplegen via [http ...]
Les " excipients à effet notoire " (avec la voie d’administration et la valeur-seuil à partir de laquelle des effets sont possibles, ainsi que des explications sur les groupes à risque) sont définis dans une directive de la Commission européenne " Excipients in the label and package leaflet of medicinal product for human use" (juillet 2003, à consulter sur [http ...]